Success in translational research: Lessons from the development of bortezomib

Nature Reviews Drug Discovery

Volumn 5, Issue 2, 2006, Pages 107-114

  Sánchez Serrano, Ibis ^a  

^a Organization of American States   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MG 519; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTECHNOLOGY; CANCER INHIBITION; CANCER MORTALITY; CANCER RESEARCH; CLINICAL TRIAL; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNDING; HUMAN; IMMUNOSURVEILLANCE; MULTIPLE MYELOMA; NONHUMAN; PATENT; PATIENT ADVOCACY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; CLINICAL PHARMACOLOGY; DRUG EFFECT; LEGAL ASPECT; PHARMACOLOGY; RESEARCH; STATISTICAL MODEL; UNITED STATES;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG INDUSTRY; INTELLECTUAL PROPERTY; MODELS, ECONOMIC; NF-KAPPA B; PHARMACOLOGY; PHARMACOLOGY, CLINICAL; PYRAZINES; RESEARCH; UNITED STATES;

EID: 33645075208     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1959     Document Type: Article

References (25)

1. von Eschenbach, A. C. A vision for the National Cancer Program in the United States. Nature Rev. Cancer 4, 820-828 (2004).
2. AAAS Report XXX. Research & Development FY 2006 [online], Intersociety Group. American Association for the Advancement of Science. Part II, Chapter 8, TABLE II-9 (2005).
3. Brower, V. The squeaky wheel gets the grease. EMBO Reports 6, 1014-1017 (2005).
4. Monga, M. & Sausville, E. A. Developmental therapeutics program at the NCl: Molecular target and drug discovery process. Leukemia 16, 520-526 (2002).
5. Mowery D. C., Nelson, R. R., Sampat, B. N. & Ziedonis, A. A. Ivory Tower and Industrial Innovation: University-Industry Technology Transfer before and after the Bayh-Dole Act. (Stanford Univ. Press, Stanford, 2004).
6. Ciechanover, A. Proteolysis: From the lysosome to ubiquitin and the proteasome. Nature Rev. Mol. Cell Biology 1, 79-87 (2005).
7. Hershko, A. & Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem. 67, 425-479 (1998).
8. Adams, J. The proteasome: A suitable anti-neoplastic target. Nature Rev. Cancer 4, 349-360 (2004).
9. Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-2kB 1 precursor protein and the activation of NF-κB. Cell 78, 773-785 (1994).
10. Adams, J. Development of the proteasome inhibitor PS-341. The Oncologist 7, 7-16 (2002).
11. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003).
12. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 348, 2487-2498 (2005).
13. Goldberg, A. in Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer. (ed. Adams, J.) 17-38 (Humana, Totowa, 2004).
14. Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
15. Adams, J. et al. Boronic ester and acid compounds. US Patent 5,780,554 (1995).
16. Barnes, P. J. & Karin, M. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336,1066-1071 (1997).
17. Teicher, B. A., Aran, G., Herbest, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638-2645 (1999).
18. Palombella, V. J. et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl Acad. Sci. USA 95, 15671-15676 (1998).
19. Adams, J. et al. Proteasome inhibitors: A novel class of potent and effective anti-tumor agents. Cancer Res. 59, 2615-2622 (1999).
20. Orlowski, R. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002).
21. Bioline[online], (2005).
22. Langreth, R. & Moukheiber, Z. Medical merlins. p5 Forbes (23 June 2003).
23. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2005 - From Laboratory to Patient. Pathways to Biopharmaceutical Innovation [online], (Washington DC, 2005).
24. Sánchez-Serrano, I. Academia-Biotech Spin-Offs: What is inside the Black-Box? Translational Research and Academia-Industry Collaborations in the Process of Drug Development. (Thesis, Tufts Univ. and Massachusetts Inst. Technol., 2004).
25. Solow, R. M. A contribution to the theory of economic growth. O. J. Econ. 70, 65-94 (1956).